Booth
1814

Join us at our booth

Come find us to learn how Oncotype DX assays use your patients' tumor biology to personalize treatment decisions in prostate cancer.

Learn more about AUA
For Your Late-Stage Patients, utilize the Oncotype DX AR-V7 Nucleus Detect Assay.

Medicare Covers Oncotype DX AR-V7 Nucleus Detect Assay

Medicare now provides 25,000 patients with metastatic castration-resistant prostate cancer (mCRPC) access to more definitive answers.

Learn more

Prospective Validation of Genomic Prostate Score Assay

Oncotype DX GPS assay established as first genomic assay with prospective clinical validation for predicting adverse pathology in newly diagnosed patients.

View the study results
For Your Early-Stage Patients, utilize Oncotype DX Genomic Prostate Score.

Follow All the Action at AUA and on Twitter

Sunday, May 5, 1:50 - 2 p.m. CDT
A 17-gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance with Dr. Peter Carroll.
Location: Podium Session PD50-06, McCormick Place, W185d
#AUA19 #Oncotype

Follow @OncotypeIQ



Biology Matters

For Your Early-Stage Patients, utilize Oncotype DX Genomic Prostrate Score. For Your Late-Stage Patients, utilize Oncotype DX AR-V7 Nucleus Detect.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™